Vicarious Surgical Inc. (RBOT) Stock Analysis

Vicarious Surgical Inc. (RBOT) Healthcare & Pipeline Overview

Vicarious Surgical Inc. develops and sells the Vicarious System, a single-incision surgical robot designed for minimally invasive surgery. Focusing initially on ventral hernia repair, the company aims to improve surgical outcomes and patient experiences through advanced robotic technology. It operates in the competitive medical device industry.

What Is the Investment Thesis for RBOT?

Vicarious Surgical Inc. presents a notable research candidate within the surgical robotics market. The company's single-incision surgical robot, the Vicarious System, targets the growing demand for minimally invasive procedures. A key value driver is the potential for expanding the applications of the Vicarious System beyond ventral hernia repair to other surgical specialties. Growth catalysts include regulatory approvals, successful clinical trials, and strategic partnerships with hospitals and surgeons. The company's success hinges on demonstrating the clinical and economic benefits of its technology compared to existing surgical methods. The company's market capitalization is $0.00B, and its beta is 1.82. Key risks include competition from established players in the surgical robotics market and the challenges of commercializing innovative medical devices. The company does not offer a dividend.

Based on FMP financials and quantitative analysis

RBOT Key Highlights

Vicarious Surgical Inc. specializes in single-incision surgical robotics, targeting minimally invasive procedures.

• The Vicarious System is designed to enhance surgical precision and reduce patient trauma.
• The company is initially focused on ventral hernia repair, a common surgical procedure.
• Vicarious Surgical operates in the competitive medical device industry.
• The company's headquarters are located in Waltham, Massachusetts.

Who Are RBOT's Competitors?

RBOT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are RBOT's Key Strengths?

Innovative single-incision surgical robot technology.

• Potential to reduce patient trauma and improve recovery times.
• Focus on a growing market for minimally invasive procedures.
• Experienced management team with expertise in robotics and surgery.

What Are RBOT's Weaknesses?

Limited product portfolio, with a focus on ventral hernia repair.

• Reliance on regulatory approvals for commercialization.
• High capital requirements for research and development.
• Small market capitalization.

What Could Drive RBOT Stock Higher?

Regulatory approvals for the Vicarious System in new surgical specialties.

• Clinical trial results demonstrating the effectiveness of the Vicarious System.
• Strategic partnerships with hospitals and surgeons to expand adoption.
• Development of new robotic capabilities to enhance the Vicarious System.
• Geographic expansion into international markets.

What Are the Key Risks for RBOT?

Listing risk — at $0.0389 the shares sit below the $1.00 minimum bid NYSE requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -39.05 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Competition from established players in the surgical robotics market.
• Technological advancements that could render the Vicarious System obsolete.
• Changes in healthcare regulations and reimbursement policies.
• Product liability claims and recalls.
• Limited financial disclosure due to OTC listing.

What Are the Growth Opportunities for RBOT?

• Expansion into New Surgical Specialties: Vicarious Surgical has the opportunity to expand the application of its Vicarious System beyond ventral hernia repair to other surgical specialties, such as colorectal surgery, gynecological surgery, and general surgery. Each of these specialties represents a significant market opportunity, potentially increasing the company's total addressable market. The timeline for this expansion depends on regulatory approvals and the successful completion of clinical trials.
• Strategic Partnerships with Hospitals and Surgeons: Collaborating with leading hospitals and surgeons can accelerate the adoption of the Vicarious System and provide valuable clinical data. These partnerships can also facilitate the training of surgeons on the use of the system and establish Vicarious Surgical as a trusted provider of surgical robotics technology. The timeline for establishing these partnerships is ongoing.
• Development of New Robotic Capabilities: Investing in research and development to enhance the capabilities of the Vicarious System, such as improved imaging, enhanced dexterity, and artificial intelligence-assisted surgery, can further differentiate the company from its competitors and attract new customers. The timeline for developing these new capabilities is dependent on technological advancements and funding.
• Geographic Expansion into International Markets: Expanding into international markets, such as Europe and Asia, can significantly increase the company's revenue potential. These markets offer large patient populations and growing demand for minimally invasive surgical procedures. The timeline for international expansion depends on regulatory approvals and the establishment of distribution networks.
• Data Analytics and Surgical Outcomes Improvement: Leveraging data analytics to analyze surgical outcomes and identify areas for improvement can enhance the effectiveness of the Vicarious System and attract new customers. By demonstrating the clinical and economic benefits of its technology, Vicarious Surgical can establish itself as a leader in surgical robotics. The timeline for implementing data analytics and surgical outcomes improvement initiatives is ongoing.

What Are RBOT's Competitive Advantages?

• Proprietary single-incision surgical robot technology.
• Patents protecting the design and functionality of the Vicarious System.
• First-mover advantage in the single-incision surgical robotics market.
• Strong relationships with leading surgeons and hospitals.

What Does RBOT Do?

Vicarious Surgical Inc., founded in 2014 and headquartered in Waltham, Massachusetts, is a medical device company focused on revolutionizing surgical procedures through robotics. The company's core product, the Vicarious System, is a single-incision surgical robot designed to virtually transport surgeons inside the patient, enabling minimally invasive surgery. This system aims to improve surgical precision, reduce patient trauma, and enhance recovery times compared to traditional open surgery methods. The Vicarious System is initially targeting ventral hernia repair, a common surgical procedure. The company's technology combines advanced robotics, virtual reality, and machine learning to provide surgeons with enhanced visualization, dexterity, and control during procedures. By utilizing a single-incision approach, Vicarious Surgical aims to minimize scarring, reduce the risk of complications, and shorten hospital stays. Vicarious Surgical operates within the broader medical device industry, specifically focusing on the surgical robotics segment. The company's competitive positioning is centered on its unique single-incision approach and its potential to expand the range of minimally invasive procedures that can be performed robotically. As of 2026, the company has 123 employees.

What Products and Services Does RBOT Offer?

• Develops single-incision surgical robots.
• Sells surgical robots for minimally invasive surgery.
• Offers the Vicarious System for ventral hernia repair.
• Uses robotics to virtually transport surgeons inside patients.
• Focuses on improving surgical precision and patient outcomes.
• Combines robotics, virtual reality, and machine learning.

How Does RBOT Make Money?

• Sells the Vicarious System surgical robot to hospitals and surgical centers.
• Generates revenue through service and maintenance contracts.
• Potential future revenue from disposable instruments and software upgrades.
• Partnerships with surgeons and hospitals for clinical trials and product development.

What Industry Does RBOT Operate In?

Vicarious Surgical Inc. operates within the medical device industry, specifically in the surgical robotics segment. This market is characterized by increasing demand for minimally invasive procedures, driven by factors such as aging populations, rising healthcare costs, and technological advancements. The competitive landscape includes established players like Intuitive Surgical, as well as emerging companies developing innovative surgical robotic systems. Vicarious Surgical aims to differentiate itself through its unique single-incision approach and its potential to expand the range of minimally invasive procedures.

Who Are RBOT's Key Customers?

• Hospitals seeking to offer minimally invasive surgical options.
• Surgical centers specializing in robotic surgery.
• Surgeons looking for advanced tools to improve surgical precision.
• Patients seeking less invasive surgical procedures with faster recovery times.

The most recent 12 insider filings for Vicarious Surgical Inc. break down as 12 sales and 0 purchases. On net that is roughly 11K shares disposed (about $53K), a signal worth weighing alongside the fundamentals.

Vicarious Surgical Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -39.05 places it in the distress zone, a signal of elevated financial risk.

Vicarious Surgical Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 4.1% above estimates on average.

Wall Street analysts project Vicarious Surgical Inc. revenue of about $0 for fiscal 2026, with EPS near $-4.07.

Company Profile

Vicarious Surgical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Stephen From. RBOT has traded publicly since 2020.

RBOT Financials

RBOT Latest News

RBOT Analyst Consensus

RBOT MoonshotScore

What Investors Ask About Vicarious Surgical Inc. (RBOT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources